A Highly Stable Human Single-Domain Antibody-Drug Conjugate Exhibits Superior Penetration and Treatment of Solid Tumors.

Yanling Wu,Quanxiao Li,Yu Kong,Zhi Wang,Cheng Lei,Ji Li,Lulu Ding,Chunyu Wang,Yaping Cheng,Yaozhu Wei,Yuanlin Song,Zhenlin Yang,Chao Tu,Yu Ding,Tianlei Ying

DOI: https://doi.org/10.1016/j.ymthe.2022.04.013

IF: 12.91

2022-01-01

Molecular Therapy

Abstract:The inefficient tumor penetration of therapeutic antibodies has hampered their effective use in treating solid tumors. Here, we report the identification of a fully human single-domain antibody (UdAb), designated as n501, targeting the oncofetal antigen 5T4. The high-resolution crystal structure indicates that n501 adopts a compact structure very similar to that of camelid nanobodies, and binds tightly to all eight leucine-rich repeats of 5T4. Furthermore, the UdAb n501 exhibits exceptionally high stability, with no apparent activity changes over 4 weeks of storage at various temperatures. Importantly, the UdAbbased antibody-drug conjugate (n501-SN38) showed much deeper tumor penetration, significantly higher tumor uptake, and faster accumulation at tumor sites than conventional IgG1-based antibody-drug conjugate (m603-SN38), resulting in improved tumor inhibition. These results highlight the potential of UdAb-based antibody-drug conjugates as a potential class of antitumor therapeutics with characteristics of high stability and strong tumor penetration for the effective treatment of solid tumors.